Skip to content

Candidacy & Timing

Bottom surgery is the most consequential single procedure in a transfeminine pathway, and the gating criteria reflect that. Most "am I ready?" questions collapse to a small list: age of majority, capacity to consent, ≥6–12 months of stable HRT, BMI in range, smoking cessation, glycemic control, and the required mental-health letters for your jurisdiction and surgeon. Everything else is local variation on those axes.

This page is candidacy and timing only — what surgeons require before they'll operate, why each criterion exists, and how to plan a 1–2 year runway. For specific procedures see Orchiectomy, Penile-Inversion Vaginoplasty, Peritoneal Pull-Through, and Vulvoplasty. For surgeon shopping, fees, and waitlists see Surgeons & Cost. For the genital electrolysis runway — which is the binding constraint on a lot of vaginoplasty timelines — see Pre-Op Hair Removal.

This page is for adults

Adolescent and pediatric genital surgery is a separate clinical and political topic with its own evidence base and review processes. It happens in a small number of multidisciplinary programs for patients suppressed in early puberty, and is out of scope here.

WPATH SOC v8 — what it actually requires

The Standards of Care v8 (Coleman et al. 2022) eligibility criteria for gender-affirming surgery in adults, consolidated into one list:

  1. Marked and sustained gender incongruence, documented by a qualified health professional.
  2. Capacity to consent.
  3. Age of majority in the relevant country (typically 18).
  4. Other possible causes of apparent gender incongruence identified and excluded.
  5. Mental-health and physical conditions that could significantly impact the outcome assessed and "reasonably well controlled."
  6. Understanding of the effect of surgery on reproduction, with reproductive options explored.
  7. At least 6 months of hormone therapy prior to genital surgery, unless medically contraindicated or not desired.

What v8 changed from v7, and what didn't actually change in practice:

  • The 12-month "real-life experience" / lived-role requirement was dropped for genital surgery.
  • The HRT prerequisite was reduced from 12 months to 6 months.
  • The explicit two-letter / two-referral structure was dropped in favor of "assessment by a qualified health professional." Insurance carriers and most surgeons did not follow — the two-letter standard persists in practice.
  • A formal DSM-5 / ICD-11 diagnosis of gender dysphoria is no longer required; documented incongruence is sufficient.

SOC v8 is the floor, not the ceiling

Surgeons and insurers can — and routinely do — require more than SOC v8 specifies. Confirm letter count, HRT-duration minimum, and BMI cap with your specific surgeon and your specific insurance plan before you book mental-health assessments. Surprises here cost months.

The HRT prerequisite — 6, 12, or 24 months

Source Minimum HRT before genital surgery Notes
WPATH SOC v8 (2022) 6 months Or documented medical reason it isn't appropriate
Endocrine Society (2017) 12 months Hembree et al.; pre-v8 baseline
Most US surgeons in practice 12 months Common across academic and private programs
Belgium / Thailand (some) 24 months Historical precedent for vaginoplasty specifically
Orchiectomy (most surgeons) 0–6 months Lower-stakes, often shorter or absent prerequisite

What the HRT prerequisite is buying you, physiologically:

  • Scrotal-skin laxity and expansion. PIV uses scrotal skin for labia majora and to extend canal depth. Estrogen plus androgen suppression thins and expands scrotal skin; PIV surgeons cite scrotal-skin quantity as the rate-limiting factor for canal depth in patients without prior puberty suppression.
  • Soft-tissue maturation. Fat redistribution to the mons; softening of penile skin used as canal lining.
  • Testicular atrophy. Modest reduction in orchiectomy intra-op blood loss.
  • Stable commitment. Non-physiological — surgeons want patients psychologically settled before an irreversible procedure.

The HRT-duration gate is convention more than evidence-based. PIV cohort studies (Buncamper 2016, Hess 2014, van der Sluis 2021) establish outcome benchmarks but don't tightly correlate HRT exposure with depth or complication rates. SOC v8's reduction to 6 months reflects this. In practice most North American surgeons will still want 12 months — plan for 12 unless you've confirmed otherwise. See Estrogens for regimens.

Pre-op estrogen pause — the shifting standard

The historical default was stop estrogen 2–4 weeks pre-op, restart 1–2 weeks post-op once ambulation resumes. The rationale: estrogen — especially oral estradiol at higher doses, and ethinylestradiol — increases venous thromboembolism risk via hepatic first-pass effects on clotting factors. Combined with surgical immobilization, this is a Virchow's-triad concern.

The evidence has moved. Multiple recent cohorts find no VTE signal from continued perioperative estrogen:

  • Kozato et al. (2021) — single-center cohort showing no VTE difference between continued vs. held estrogen across ~407 gender-affirming surgery patients (Journal of Clinical Endocrinology & Metabolism).
  • Hontscharuk et al. (2021) — perioperative trans hormone management review concluding insufficient evidence to mandate routine pause (Plastic and Reconstructive Surgery).
  • Kim et al. (2024) — 953-patient FFS cohort with one VTE event total (0.10%) on continued perioperative estrogen (Plast Reconstr Surg).
  • Boskey et al. (2019) — no VTE signal in an adolescent gender-affirming-surgery cohort.

Common 2024-era practice is to continue transdermal estradiol through surgery, switch oral patients to transdermal about 4 weeks pre-op, and only fully pause in patients with elevated baseline VTE risk. The universal 2-week pause is no longer treated as standard.

Modifiers that still argue for pause or transdermal switch:

  • Oral ethinylestradiol (rare in trans care now; strongly thrombogenic).
  • High-dose oral estradiol (≥6 mg/day) with other risk factors — BMI >30, smoking history, factor V Leiden, age >40.
  • Long-haul flights to a surgery destination (Thailand, Mexico) compounding the immobilization picture.

Spironolactone is typically stopped pre-op for volume and electrolyte control during anesthesia. GnRH agonists are typically continued. Confirm specifics with your surgical team — protocols vary.

Surgeon / Program Historical pre-op estrogen pause Notes
Marci Bowers 2 weeks Restart on ambulation
Crane Center 2 weeks Some flexibility for transdermal
Bluebond-Langner (NYU) 2–4 weeks Trending toward continuation
Suporn / Chettawut (Thailand) 2–3 weeks
Ghent (Monstrey successor) 2 weeks
Brassard / GrS Montréal 3 weeks

These are 2023-era reported defaults from patient-facing materials. Verify current protocol with the specific surgeon — practice is moving.

BMI thresholds

Vaginoplasty surgeons cap somewhere between BMI 30 and BMI 35. Orchiectomy thresholds are usually higher or absent. The rationale is wound healing, anesthesia risk, technical difficulty with deep dissection in obese pelvises, and post-op dilation logistics.

Surgeon / Program Vaginoplasty BMI cap Notes
Marci Bowers ~32 Some flexibility, case-by-case
Crane Center 33 Will sometimes go higher
NYU (Bluebond-Langner / Zhao) 35
Brassard / GrS Montréal 30 Stricter than most
Suporn (Thailand) 30
Chettawut 28 Notably strict
Ghent (Monstrey successor) 30
Most US academic programs 30–35

The peer-reviewed BMI-stratified data are thin. Gaither et al. (2018) — 330 PIV patients — and Ives et al. (2019) — demographic outcome trends — both show modestly elevated wound complications above BMI 30 without a catastrophic threshold. The BMI cap is a soft, surgeon-specific number. Patients near a cap can sometimes negotiate, particularly with academic programs. Numbers above are 2023-era; re-verify against current surgeon materials.

Smoking cessation

4–8 weeks of confirmed cessation pre-op is universal. Nicotine in any form — cigarettes, vapes, patches, gum, snus — impairs wound healing through vasoconstriction and tissue hypoxia. Vaginoplasty is exquisitely sensitive: necrosis of the neoclitoris or labial flaps from compromised perfusion is a major complication, and active smoking approximately doubles odds of dehiscence and surgical-site infection (Sørensen 2012 — OR 2.07 dehiscence, 1.79 infection).

  • Most surgeons require 6–8 weeks cessation pre-op and 4–6 weeks post-op.
  • Cotinine testing on the morning of surgery is common at higher-volume US programs (Crane, Bowers); a positive result cancels surgery.
  • Cannabis policies vary. Some surgeons treat smoked cannabis the same as tobacco; others permit edibles up to about 1 week pre-op.

This is the single highest-leverage modifiable risk factor. Don't try to hide it — cotinine testing catches it, and cancellation cascades into months of re-scheduling.

Diabetes and glycemic control

HbA1c < 7.5% is the typical cutoff, with a few programs accepting up to 8.0 (Crane, NYU) and Bowers landing tighter at 7.0–7.5. Hyperglycemia impairs wound healing and elevates infection risk; the perineum is a high-bacterial- load surgical field. Patients on insulin need an endocrinology clearance letter and a peri-operative insulin plan; type 1 diabetes is not a contraindication but adds logistical complexity.

Mental-health letter requirements

This is the most variable gating criterion across regions, and the one most likely to surprise patients. There is no peer-reviewed evidence that two letters produce better outcomes than one — the two-letter standard is institutional carry-over from SOC v6/v7. SOC v8 simplified the letter requirement; insurers and most individual surgeons did not follow. Orchiectomy typically requires one letter where vaginoplasty requires two.

Region Vaginoplasty letters typically required Notes
US (insurance) 2 (one mental-health, one prescriber/2nd MHP) Most Blues, Aetna, UHC trans-inclusive plans require 2 in policy
US (cash, SOC v8) Often 1 Bowers, Crane sometimes accept 1 for cash patients
UK (NHS) 2 GIC clinician referrals GIC waits (5–7+ years) are the real constraint
UK (private) Typically 2 Nuffield-affiliated surgeons usually want 2
Canada (ON, BC, QC) 2 assessments by approved clinicians Provincial pre-approval; QC requires one psychiatrist
Germany 2 Gutachten (in flux post-2024 reform) TSG repeal in 2024; most surgeons still requesting 2
Netherlands Structured Amsterdam-protocol assessment Functions like 2 letters in practice
Spain 0–2 depending on autonomous community Self-determination laws reduce in some regions
Belgium (Ghent) 2 Historical standard

Letter validity is typically 12 months — schedule assessments so both letters are still current at the surgical date, not at booking.

Confirm letter count with the specific surgeon and the specific insurance plan before scheduling assessments. The single-letter SOC-v8 reading does not override insurer policy. Patients lose months by lining up one letter and discovering the insurer wants two.

Sequencing with FFS, BA, and other procedures

Why FFS and bottom surgery aren't combined

  • Anesthesia time. Vaginoplasty is 4–7 hours; FFS is 6–10 hours. Combined would exceed safe single-anesthesia windows (>10–12 hours elevates DVT, rhabdomyolysis, and anesthesia-mortality risk).
  • Positioning conflict. Vaginoplasty is performed in dorsal lithotomy; FFS requires supine head-extension. Mid-operation repositioning adds contamination and time.
  • Recovery conflict. FFS recovery wants upright positioning to drain facial edema; vaginoplasty wants bed rest with leg elevation for 5–7 days. The two protocols are directly contradictory in week 1.
  • Hair-removal timeline. PIV and most vaginoplasty techniques require pre-op genital electrolysis (typically 6–12 months). FFS-first naturally occupies that interval.
  • Letter / insurance cycles. Each procedure has its own assessment cycle in many systems.

Common sequences

Sequence When it fits
FFS → vaginoplasty (6–12 months later) Most common. Lets FFS swelling resolve; uses the gap for genital hair removal
Orchiectomy → FFS → vaginoplasty When dropping antiandrogens early matters; orchi is short and travel-friendly
Vaginoplasty → FFS Less common; usually dysphoria-driven. Recovery harder to combine with subsequent FFS prep
BA + FFS (single session) Frequently combined; positioning compatible, anesthesia time tolerable
BA + vaginoplasty Done occasionally at high-volume centers; less common
Tracheal shave + FFS or + vaginoplasty Often added; ~30 min anesthesia overlap

See Procedure Staging for the full FFS staging logic.

Hair-removal scheduling

Genital electrolysis (or laser, where surgeon-accepted) is upstream of vaginoplasty and is the most commonly missed dependency. Most surgeons want the final electrolysis session ≥6–8 weeks before vaginoplasty so inflammation can settle. Plan backwards from the surgical date — see Pre-Op Hair Removal for surgeon-specific clearance maps.

Age gating

Most surgeons require ≥18 for vaginoplasty. Some accept 17 with parental consent, especially for orchiectomy and patients suppressed in early puberty whose tissue volumes won't increase with waiting. Insurance often refuses <18 regardless of surgeon willingness. SOC v8 endorses individualized adolescent assessment in Chapter 6 without setting a hard minimum age.

Where the evidence is weak

The HRT-duration prerequisite, BMI caps, and letter requirements are convention and policy, not RCT-grade evidence. Long-term cohort data on bottom-surgery regret are reassuring — Bustos et al. (2021) meta-analysis pooled regret at ~1%, and Wiepjes et al. (2018) Amsterdam cohort reported similarly low rates over decades — but these are not procedure- or HRT-duration-specific. None of this changes the gating you'll face; it does mean honest surgeons disagree on the specific numbers.

Sources

Primary guidelines

Pre-op estrogen / VTE

  • Kozato A, Fox GWC, Yong PC, et al. (2021) — No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery (J Clin Endocrinol Metab).
  • Hontscharuk R, Alba B, Hamidian Jahromi A, Schechter L. (2021) — Perioperative Transgender Hormone Management: Avoiding Venous Thromboembolism and Other Complications (Plast Reconstr Surg).
  • Kim S et al. (2024) — Perioperative Estrogen Hormonal Therapy Does Not Increase Venous Thromboembolism Risk in Facial Feminization Surgery (Plast Reconstr Surg) — 953-patient FFS cohort; 1 VTE event total.
  • Boskey ER, Taghinia AH, Ganor O. (2019) — Association of Continuing vs Holding Hormone Therapy in Trans Patients Undergoing Gender-Affirming Surgery.

Vaginoplasty outcomes and BMI

  • Buncamper ME et al. (2016) — Surgical Outcome After Penile Inversion Vaginoplasty: A Retrospective Study of 475 Transgender Women (Plast Reconstr Surg) — VUmc cohort.
  • van der Sluis WB et al. (2021) — long-term follow-up after intestinal vaginoplasty (J Sex Med).
  • Gaither TW et al. (2018) — Postoperative Complications following Primary Penile Inversion Vaginoplasty among 330 Male-to-Female Transgender Patients (J Urol).
  • Hess J et al. (2014) — Satisfaction with Male-to-Female Gender Reassignment Surgery (Dtsch Arztebl Int).

Long-term outcomes and regret

  • Wiepjes CM et al. (2018) — The Amsterdam Cohort of Gender Dysphoria Study (1972–2015) (J Sex Med).
  • Bustos VP et al. (2021) — Regret after Gender-Affirmation Surgery: A Systematic Review and Meta-Analysis of Prevalence (Plast Reconstr Surg Glob Open).

General surgical risk